Abstract
Purpose of Review
For patients undergoing evaluation and treatment of cancers, symptom management is a critical component of their treatment plan. For some patients, symptoms may become intractable or refractory to common therapies. Here, we review treatment options for these severe symptom conditions.
Recent Findings
Medication options and regimens have improved to treat refractory symptoms. Medications can be tailored to treat chemotherapy-induced nausea and vomiting based on current guidelines. Interventions such as venting gastrostomy can mitigate symptoms associated with malignant bowel obstruction, when life expectancy is long enough to realize this benefit. Opiates can reduce refractory dyspnea, consistent with guidelines from the American Thoracic Society. Interventional therapies for intractable pain, such as neurolytic blocks and intrathecal pumps, have shown promise in managing symptoms when traditional therapies have been ineffective.
Summary
Refractory symptoms can be managed in cancer care. The use of multimodal therapies delivered by interdisciplinary teams appears to be the most effective way to approach these clinical situations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Pharo GH. Pharmacologic Management of Cancer Pain. JAOA Supplement 5. 2005;105(11):S21–S28.
Wickham, RJ. Nausea and vomiting not related to cancer therapy: intractable problem or clinical challenge? J Adv Pract Oncol. 2020;11(5):476–488.
Heskuth PJ. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38:2782–97.
Navari RM. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Ther. 2018;11:6459–78.
• Navari RM. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42 This study demonstrated significant benefit of adding olanzapine, a relatively inexpensive medication, to treat or prevent CINV. Results showed benefit in reducing vomiting as well as nausea itself. Most side effects were shown to be transient.
Harder SG. Antiemetic use of olanzapine in patients with advanced cancer: results from an open label multicenter study. Support Care Cancer. 2019;27:2849–56.
Peiffer C. Morphine-induced relief of dyspnea: what are the mechanisms. Am J Respir Crit Care Med. 2011;184:867–9.
Landrum LM. Comprehensive care in gynecologic oncology: the importance of palliative care. Gynecol Oncol. 2015;137:193–202.
Chan WL. Effective management of breathlessness in advanced cancer patients with a program-based, multidisciplinary approach: the "SOB Program" in Hong Kong. J Pain Symptom Manag. 2016;51:623–7.
Patel MS. Strategies for the optimal management of dyspnea in cancer patients with advanced illnesS. Oncology. 2018;583-85:590.
Mularski RA. Managing dyspnea in advanced chronic obstructive pulmonary disease: balancing all the evidence. Ann Am Thorac Soc. 2015;12(7):978–80.
Mahler DA. Recent advanced in dyspnea. Chest. 2015;147:232–41.
Lanken PN. An official American thoracic society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177:912–27.
Kamal AH. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med. 2012;15:106–14.
Johnson MB. Gaps in the evidence base of opioids of refractory breathlessness. A future work plan? J Pain Symptom Manag. 2012;43(3):614–24.
Buckholz GT. Nonpharmacologic management of dyspnea. Curr Opin Support Palliat Care. 2009;3:98–102.
Van den Beuken-van Everdingen MHJ. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49.
McPherson ML. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manag. 2019;57:635–645.e4.
• Cheung KWA. The use of ketamine in the management of refractory cancer pain in a palliative care unit. Ann Palliat Med. 2020;9(6):4478–4489. Ketamine infusions appear to show significant promise in reducing intractable pain and subsequently reducing patients’ overall medication needs. These intermittent infusion therapies may be incorporated into patients’ treatment plans through brief hospitalizations on oncology or palliative care units.
Ferrer-Mileo L. Efficacy of cryoablation to control cancer pain: a systematic review. Pain Practice. 2018;18(8):1083–98.
Smith TJ. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.
Bruel BM. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17:2404–21.
Nipp RD. Differential effects of early palliative care based on the age and sex of patients with advanced cancer from a randomized controlled trial. Palliat Med. 2018;32(4):757–66.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None of the authors has any potential conflicts of interest to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Palliative Medicine
Rights and permissions
About this article
Cite this article
Dziedzic, K.L., Albert, R.H. Management of Intractable Symptoms in Oncologic Care. Curr Oncol Rep 23, 93 (2021). https://doi.org/10.1007/s11912-021-01082-2
Accepted:
Published:
DOI: https://doi.org/10.1007/s11912-021-01082-2